Celsion is a clinical stage biotechnology company. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for the treatment of ovarian cancer. ThermoDox®, Co.'s proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications, which is being managed though Co.'s wholly owned subsidiary, Celsion GmbH. Additionally, Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
|
Free CLSN Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |